Abarelix

Drug Profile

Abarelix

Alternative Names: Abarelix-depot-F; Abarelix-depot-M; Abarelix-L; Beta-abarelix; Plenaxis; PPI 149; R 3827; β-abarelix

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University
  • Developer Speciality European Pharma
  • Class Oligopeptides
  • Mechanism of Action LHRH receptor antagonists; Testosterone antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Prostate cancer
  • Discontinued Endometriosis

Most Recent Events

  • 21 Sep 2017 Launched for Prostate cancer in Luxembourg and Belgium (IM) before September 2017 (Speciality European Pharma website, September 2017)
  • 15 Dec 2016 Biomarkers information updated
  • 27 Feb 2015 Launched for Prostate cancer in Denmark and Netherlands (IM) prior to February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top